Department of Nuclear Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 707, Sec. 3, Chung-Yang Rd., Hualien, 97002, Taiwan; Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.
Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Acad Radiol. 2020 Aug;27(8):e183-e192. doi: 10.1016/j.acra.2019.10.015. Epub 2019 Nov 21.
Radiomic analysis of F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) images enables the extraction of quantitative information of intratumour heterogeneity. This study investigated whether the baseline F-FDG PET/CT radiomics can predict treatment response and survival outcomes in patients with Hodgkin lymphoma (HL).
Thirty-five patients diagnosed with HL who underwent F-FDG PET/CT scans before and during chemotherapy were retrospectively enrolled in this investigation. For each patient, we extracted 709 radiomic features from pretreatment PET/CT images. Clinical variables (age, gender, B symptoms, bulky tumor, and disease stage) and radiomic signatures (intensity, texture, and wavelet) were analyzed according to response to therapy, progression-free survival (PFS), and overall survival (OS). Receiver operating characteristic curve, logistic regression, and Cox proportional hazards model were used to examine potential predictive and prognostic factors.
High-intensity run emphasis (HIR) of PET and run-length nonuniformity (RLNU) of CT extracted from gray-level run-length matrix (GLRM) in high-frequency wavelets were independent predictive factors for the treatment response (odds ratio [OR] = 36.4, p = 0.014; OR = 30.4, p = 0.020). Intensity nonuniformity (INU) of PET and wavelet short run emphasis (SRE) of CT from GLRM and Ann Arbor stage were independently related to PFS (hazard ratio [HR] = 9.29, p = 0.023; HR = 18.40, p = 0.012; HR = 7.46, p = 0.049). Zone-size nonuniformity (ZSNU) of PET from gray-level size zone matrix (GLSZM) was independently associated with OS (HR = 41.02, p = 0.001). Based on these factors, a prognostic stratification model was devised for the risk stratification of patients. The proposed model allowed the identification of four risk groups for PFS and OS (p < 0.001 and p < 0.001).
HIRGLRM and RLNUGLRM in high-frequency wavelets serve as independent predictive factors for treatment response. ZSNUGLSZM, INUGLRM, and wavelet SREGLRM serve as independent prognostic factors for survival outcomes. The present study proposes a prognostic stratification model that may be clinically beneficial in guiding risk-adapted treatment strategies for patients with HL.
基于 F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(F-FDG PET/CT)的放射组学分析可以提取肿瘤内异质性的定量信息。本研究旨在探讨基线 F-FDG PET/CT 放射组学特征能否预测霍奇金淋巴瘤(HL)患者的治疗反应和生存结局。
回顾性纳入 35 例经化疗前和化疗期间 F-FDG PET/CT 扫描诊断为 HL 的患者。为每位患者从预处理 PET/CT 图像中提取 709 个放射组学特征。根据治疗反应、无进展生存期(PFS)和总生存期(OS),分析临床变量(年龄、性别、B 症状、巨大肿块和疾病分期)和放射组学特征(强度、纹理和小波)。采用受试者工作特征曲线、逻辑回归和 Cox 比例风险模型分析潜在的预测和预后因素。
基于灰度游程长度矩阵(GLRM)的高频小波中的高亮度游程强调(HIR)和 CT 的游程长度非均匀性(RLNU)是治疗反应的独立预测因素(比值比 [OR] = 36.4,p = 0.014;OR = 30.4,p = 0.020)。基于 GLRM 的 PET 的强度非均匀性(INU)和 CT 的小波短运行强调(SRE)以及 Ann Arbor 分期与 PFS 独立相关(风险比 [HR] = 9.29,p = 0.023;HR = 18.40,p = 0.012;HR = 7.46,p = 0.049)。基于灰度大小区矩阵(GLSZM)的 PET 的区尺寸非均匀性(ZSNU)与 OS 独立相关(HR = 41.02,p = 0.001)。基于这些因素,为患者的风险分层制定了一个预后分层模型。所提出的模型可以为 PFS 和 OS 识别四个风险组(p<0.001 和 p<0.001)。
基于 GLRM 的 HIR 和高频小波中的 RLNUGLRM 是治疗反应的独立预测因素。基于 GLSZM 的 ZSNU、GLRM 的 INU 和小波 SREGLRM 是生存结局的独立预后因素。本研究提出了一种预后分层模型,可能有助于指导 HL 患者的风险适应治疗策略。